“Novartis and its team of greedy doctors betrayed that trust by duping patients into taking medication as part of a fraudulent kickback scheme and cheated the state out of millions while putting the health and safety of countless individuals at risk.
The agreement resolves allegations that from January 2002 to November 2011, Novartis paid kickbacks to doctors to prescribe Lotrel, Valturna, Starlix, Tekamlo, Diovan HCT, Tekturna HCT, and Exforge HCT, and that between January 2010 and November 2011, Novartis also did so for Exforge, Diovan, and Tekturna.
Corporate conductAllegationAgainst
Novartis is accused of prescription drug price fixing
New Jersey Office of Attorney General alleges Novartis engaged in prescription drug price fixing with Sandoz.
Acting AG Davenport Files Multistate Complaint Against Novartis and Sandoz Alleging Prescription Drug Price Fixing - New Jersey Office of Attorney General
Corporate conductSettlementAgainst
Novartis settles fraud claims over doctor inducements
Novartis settled a civil fraud lawsuit alleging it provided doctors with cash, meals, and alcohol to induce prescriptions of its cardiovascular and diabetes drugs reimbursed by federal healthcare programs.
Acting Manhattan U.S. Attorney Announces $678 Million Settlement Of Fraud Lawsuit Against Novartis Pharmaceuticals For Operating Sham Speaker Programs Through Which It Paid Over $100 Million To Doctors To Unlawfully Induce Them To Prescribe Novartis Drugs
Under the settlement, NOVARTIS will pay a total of $678,000,000, of which (i) $591,442,008.92 will be paid to the United States as False Claims Act damages, (ii) $38,406,717.42 will be forfeited to the United States as proceeds of violations of the Anti-Kickback Statute; and (iii) $48,151,273.66 will be paid to various States.
NOVARTIS’s compliance training materials suggested that emails advocating illegal kickbacks were improper in part because they “reflect[] ignorance of the import of written communications, and put[] the Company at risk.” NOVARTIS’s Chief Compliance Officer also stated in training presentations: “If you don't have to write it, don’t.
Lampert said: “The various kickback schemes employed by Novartis threatened the impartiality of medical decision-making and the financial integrity of Medicare and Medicaid.
For example, Novartis admitted that in Long Island, at least one sales representative organized fraudulent speaker programs by arranging for a restaurant to create fake receipts to make it appear that a dinner had taken place, and then used the budgeted funds to purchase gift cards that were distributed to high-prescribing doctors.
In its court filings, the New York Attorney General’s Office (NYAG) alleged that Novartis paid doctors to speak about certain drugs at sham events, which were falsely advertised as educational, in an attempt to evade the law.
Novartis-315 Page 2 of 19 On April 26, 2013, the United States intervened in the Civil Action against Novartis by filing a Notice of Election to Intervene and Complaint -in-Intervention, in which it is assert ed that claims against Novartis under the FCA and common law.
The company admitted giving doctors cash, golf and fishing trips, and lavish meals at some of the nation’s fanciest restaurants to induce them to prescribe Novartis cardiovascular and diabetes drugs that were reimbursed by federal healthcare programs, the government said in a release.
The settlement resolves a 2011 whistleblower lawsuit accusing Novartis of violating the federal False Claims Act and Anti-Kickback Statute. The company admitted giving doctors cash, golf and fishing trips, and lavish meals at some of the nation’s fanciest restaurants to induce them to prescribe Novartis cardiovascular and diabetes drugs that were reimbursed by federal healthcare programs, the government said in a release.
Federal authorities alleged that Novartis earned hundreds of millions of dollars in federal reimbursements for selling drugs sold by doctors benefiting from tens of thousands of sham educational events at high-end restaurants and other venues.
Novartis AG (NYSE: NVS) has reached a $678 million settlement in a civil fraud lawsuit that alleged the company bribed doctors at speaker events it organized.
Department of Defense - Office of Inspector General’s Defense Criminal Investigative Service (“DCIS”), and Christopher Algieri, Special Agent in Charge the Department of Veterans Affairs, Office of Inspector General, Northeast Field Office (“VA OIG”), announced today that the United States has settled a civil fraud lawsuit against NOVARTIS PHARMACEUTICALS CORPORATION (“NOVARTIS”), part of Swiss drug manufacturer Novartis International AG, alleging that NOVARTIS violated the federal False Claims Act and Anti-Kickback Statute by providing doctors with cash payments, recreational outings, lavish meals, and expensive alcohol to induce them to prescribe NOVARTIS cardiovascular and diabetes drugs reimbursed by federal healthcare programs.
Consider using the phone.” Under the settlement, NOVARTIS will pay a total of $678,000,000, of which (i) $591,442,008.92 will be paid to the United States as False Claims Act damages, (ii) $38,406,717.42 will be forfeited to the United States as proceeds of violations of the Anti-Kickback Statute; and (iii) $48,151,273.66 will be paid to various States. The settlement also requires NOVARTIS to reform its business practices.
FOR IMMEDIATE RELEASE Wednesday, July 1, 2020 U.S. Attorneys » Southern District of New York » News » Press Releases Department of Justice U.S. Attorney’s Office Southern District of New York Acting Manhattan U.S. Attorney Announces $678 Million Settlement Of Fraud Lawsuit Against Novartis Pharmaceuticals Corporation For Operating Sham Speaker Programs Through Which It Paid Over $100 Million To Doctors To Unlawfully Induce Them To Prescribe No Novartis Admits to Certain Conduct Alleged in the Lawsuit and Agrees to Strict Limitations on Its Ability to Conduct Future Speaker Programs Audrey Strauss, the Acting United States Attorney for the Southern District of New York, William F.
Under the CIA, Novartis must significantly reduce the number of programs and the number of paid physicians, and can no longer pay for inherently-risky in-person programs.” HHS-OIG Special Agent in Charge Scott J.
Acting Manhattan U.S. Attorney Announces $678 Million Settlement Of Fraud Lawsuit Against Novartis Pharmaceuticals Corporation For Operating Sham Speaker Programs Through Which It Paid Over $100 Million To Doctors To Unlawfully Induce Them To Prescribe No | Oversight.gov
Lampert said: “The various kickback schemes employed by Novartis threatened the impartiality of medical decision-making and the financial integrity of Medicare and Medicaid.
Under the settlement, NOVARTIS will pay a total of $678,000,000, of which (i) $591,442,008.92 will be paid to the United States as False Claims Act damages, (ii) $38,406,717.42 will be forfeited to the United States as proceeds of violations of the Anti-Kickback Statute; and (iii) $48,151,273.66 will be paid to various States.
NOVARTIS’s compliance training materials suggested that emails advocating illegal kickbacks were improper in part because they “reflect[] ignorance of the import of written communications, and put[] the Company at risk.” NOVARTIS’s Chief Compliance Officer also stated in training presentations: “If you don't have to write it, don’t.
Department of Defense - Office of Inspector General’s Defense Criminal Investigative Service (“DCIS”), and Christopher Algieri, Special Agent in Charge the Department of Veterans Affairs, Office of Inspector General, Northeast Field Office (“VA OIG”), announced July 1, 2020, that the United States has settled a civil fraud lawsuit against NOVARTIS PHARMACEUTICALS CORPORATION (“NOVARTIS”), part of Swiss drug manufacturer Novartis International AG, alleging that NOVARTIS violated the federal False Claims Act and Anti-Kickback Statute by providing doctors with cash payments, recreational outings, lavish meals, and expensive alcohol to induce them to prescribe NOVARTIS cardiovascular and diabetes drugs reimbursed by federal healthcare programs.
Lampert, Special Agent in Charge of HHS-OIG’s New York Regional Office, Leigh-Alistair Barzey, Special Agent in Charge of the Northeast Field Office of the U.S. Department of Defense - Office of Inspector General’s Defense Criminal Investigative Service (“DCIS”), and Christopher Algieri, Special Agent in Charge the Department of Veterans Affairs, Office of Inspector General, Northeast Field Office (“VA OIG”), announced July 1, 2020, that the United States has settled a civil fraud lawsuit against NOVARTIS PHARMACEUTICALS CORPORATION (“NOVARTIS”), part of Swiss drug manufacturer Novartis International AG, alleging that NOVARTIS violated the federal False Claims Act and Anti-Kickback Statute by providing doctors with cash payments, recreational outings, lavish meals, and expensive alcohol to induce them to prescribe NOVARTIS cardiovascular and diabetes drugs reimbursed by federal healthcare programs.
Acting Manhattan U.S. Attorney Announces $678 Million Settlement Of Fraud Lawsuit Against Novartis Pharmaceuticals Corporation For Operating Sham Speaker Programs Through Which It Paid Over $100 Million To Doctors To Unlawfully Induce Them To Prescribe No | Department of Veterans Affairs OIG
Corporate conductSettlementAgainst
Novartis settles for $390 million over kickbacks
Novartis agreed to a $390 million settlement after being accused of giving kickbacks to specialty pharmacies for recommending Exjade and Myfortic.
Southern District of New York | Manhattan U.S. Attorney Announces $370 Million Civil Fraud Settlement Against Novartis Pharmaceuticals For Kickback Scheme Involving High-Priced Prescription Drugs, Along With $20 Million Forfeiture Of Proceeds From The Scheme | United States Department of Justice
District Judge Colleen McMahon approved a settlement to resolve the Government’s claims against NOVARTIS.
Preet Bharara, the United States Attorney for the Southern District of New York, Diego Rodriguez, the Assistant Director-in-Charge of the New York Office of the Federal Bureau of Investigation (“FBI”), Gregory E. Demske, Chief Counsel to the Inspector General of the U.S. Department of Health and Human Services (“HHS-OIG”), and Scott J. Lampert, Special Agent in Charge of HHS-OIG’s New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp. (“NOVARTIS”) in a civil fraud lawsuit based on claims that NOVARTIS gave kickbacks to specialty pharmacies in return for recommending two of its drugs, Exjade and Myfortic.
Lampert, Special Agent in Charge of HHS-OIG’s New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp. (“NOVARTIS”) in a civil fraud lawsuit based on claims that NOVARTIS gave kickbacks to specialty pharmacies in return for recommending two of its drugs, Exjade and Myfortic.
Lampert said: “Novartis’s kickbacks and other aggressive sales tactics, as alleged in this case, threatened the impartiality of medical decision-making and the financial integrity of Medicare and Medicaid.
Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed to pay over $642 million in separate settlements resolving claims that it violated the False Claims Act (FCA).
Preet Bharara, the United States Attorney for the Southern District of New York, Diego Rodriguez, the Assistant Director-in-Charge of the New York Office of the Federal Bureau of Investigation ("FBI"), Gregory E. Demske, Chief Counsel to the Inspector General of the U.S. Department of Health and Human Services ("HHS-OIG"), and Scott J. Lampert, Special Agent in Charge of HHS-OIG's New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp. ("NOVARTIS") in a civil fraud lawsuit based on claims that NOVARTIS gave kickbacks to specialty pharmacies in return for recommending two of its drugs, Exjade and Myfortic.
Manhattan U.S. Attorney Announces $370 Million Civil Fraud Settlement Against Novartis Pharmaceuticals For Kickback Scheme Involving High-Priced Prescription Drugs, Along With $20 Million Forfeiture Of Proceeds From The Scheme | Office of Inspector General | Government Oversight | U.S. Department of Health and Human Services
Lampert, Special Agent in Charge of HHS-OIG's New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp. ("NOVARTIS") in a civil fraud lawsuit based on claims that NOVARTIS gave kickbacks to specialty pharmacies in return for recommending two of its drugs, Exjade and Myfortic.
Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed to pay over $642 million in separate settlements resolving claims that it violated the False Claims Act (FCA).
The State contends that it has certain civil and administrative causes of action against Novartis for engaging in the following conduct (the “Covered Conduct”): The State contends that Novartis paid kickbacks and violated the federal Anti-Kickback Statutes as follows: (a) from in or about February 2007 to in or about May 2012, Novartis (i) gave patient referrals, discounts and rebates to Accredo Health Group, Inc. (“Accredo”), BioScrip, Inc. (“BioScrip”), and U.S.Page 2 of 14
The State contends that it has certain civil and administrative causes of action against Novartis for engaging in the following conduct (the "Covered Conduct"): The State contends that Novartis paid kickbacks and violated the federal Anti Kickback Statute as follows: (a) from in or about February 2007 to in or about May 2012, Novartis (i) gave patient referrals, discounts and rebates to Accredo.
8/96 Page·3 ofl4 Bioservices Corporation (“US Bioservices”) to induce these pharmacies to recommend to patients that they order Exjade refills and (ii) thereby caused Accredo, BioScrip and US Bioservices to submit false claims to Medicaid for reimbursement for Exjade that were not eligible for payment; and (b) from in or about June 2004 to in or about December 2013, Novartis (i) gave discounts and/or rebates to specialty pharmacies (including Transcript Pharmacy, Bryant’s Pharmacy and Healthcare Center, Kilgore’s Medical Pharmacy, Baylor Health Care System, and Twenty-Ten Pharmacy) in return for their agreement to recommend to physicians to prescribe Myfortic instead of the competitor drug CellCept and (ii) thereby caused these pharmacies to submit false claims to Medicaid for reimbursement for Myfortic that were not eligible for payment. F.
Lampert, Special Agent in Charge of HHS-OIG’s New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp. (“NOVARTIS”) in a civil fraud lawsuit based on claims that NOVARTIS gave kickbacks to specialty pharmacies in return for recommending two of its drugs, Exjade and Myfortic.
Preet Bharara, the United States Attorney for the Southern District of New York, Diego Rodriguez, the Assistant Director-in-Charge of the New York Office of the Federal Bureau of Investigation (“FBI”), Gregory E. Demske, Chief Counsel to the Inspector General of the U.S. Department of Health and Human Services (“HHS-OIG”), and Scott J. Lampert, Special Agent in Charge of HHS-OIG’s New York Regional Office, announced a $390 million settlement against NOVARTIS Pharmaceuticals Corp. (“NOVARTIS”) in a civil fraud lawsuit based on claims that NOVARTIS gave kickbacks to specialty pharmacies in return for recommending two of its drugs, Exjade and Myfortic.
Manhattan U.S. Attorney Announces $370 Million Civil Fraud Settlement Against Novartis Pharmaceuticals for Kickback Scheme Involving High-Priced Prescription Drugs, Along with $20 Million Forfeiture of Proceeds from the Scheme — FBI
District Judge Colleen McMahon approved a settlement to resolve the Government’s claims against NOVARTIS.
Under that settlement, NOVARTIS agrees to (i) pay $370,000,000 to resolve the federal and state false claims act claims, (ii) forfeit $20 million as proceeds from the scheme under the federal civil forfeiture statute, (iii) make extensive admissions concerning its relationship with specialty pharmacies, and (iv) amend its corporate integrity agreement with HHS-OIG to subject NOVARTIS’s specialty pharmacy relationships to independent review and extend the term of that agreement by five years.
13 release and refrain from instituting, directing, or maintaining any administrative action seeking exclusion from Medicare, Medicaid, and other Federal health care programs (as defined in 42 U.S.C. § 1320a -7b(f)) against Novartis under 42 U.S.C. § 1320a -7a (Civil Monetary Penalties Law) or 42 U.S.C. § 1320a -7(b)(7) (permissive exclusion for fraud, kickbacks, and other prohibited activities) for the Covered Conduct, except as reserved in Paragraph 11 (concerning excluded claims), below, and as reserved in this Paragraph.
those drugs to be submitted to and paid by Medicare, Medicaid, the Department of Veterans Affairs and TRICARE, in violation of the FCA; and (ii) from January 1, 2010, through November 21, 2011, Novartis paid remuneration in the form of cash, meals, alcohol, hotels, travel, entertainment, and honoraria payments to HCPs who spoke at or attended Novartis speaker events, roundtables, speaker training meetings or lunch-n-learns to induce them to prescribe Diovan, Tekturna, and Exforge in violation of the AKS, and thereby caused false claims for prescriptions for Diovan, Tekturna, and Exforge to be submitted to and paid by Medicare, Medicaid, the Department of Veterans Affairs and TRICARE, in violation of the FCA.
Corporate conductConfirmedAgainst
Novartis transfers drugs at government-dictated prices
Novartis transferred its products to third parties at government-dictated prices far below market values after ENTRESTO® was included in the Program.
After its innovative drug ENTRESTO® was selected for inclusion in the Program, Novartis was forced to perform sham “negotiations” over a purported “maximum fair price” for its drug, execute a series of “agreements” misrepresenting that process to the public, and then transfer its products to third parties at government-dictated prices far below market values.
Corporate conductSettlementAgainst
Novartis AG agreed to pay $25 million to settle FCPA violations related to pay-to-prescribe schemes in China
The Securities and Exchange Commission today announced that Novartis AG has agreed to pay $25 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales.
Novartis AG - The Swiss-based pharmaceutical company agreed to pay $25 million to settle charges that it violated the FCPA when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales.
The Securities and Exchange Commission today announced that Novartis AG has agreed to pay $25 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales.
Novartis consented to the order without admitting or denying the findings, and agreed to pay $21.5 million in disgorgement of profits plus $1.5 million in prejudgment interest and a $2 million penalty.
Taking its allegations as true, Novartis and Vetter sought to deceive the PTO and the market at large by concealing Vetter’s inventorship.
Corporate conductSettlementAgainst
Novartis AG agreed to pay $112 million to settle FCPA violations
The Securities and Exchange Commission today announced that Novartis AG, a global pharmaceutical and healthcare company headquartered in Basel, Switzerland, has agreed to pay over $112 million to settle charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA).
The order also finds that Novartis lacked sufficient internal accounting controls within its former Alcon business in China from 2013 to 2015, which used forged contracts as part of local financing arrangements that generated large losses and resulted in Novartis and Alcon writing off more than $50 million in bad debt.
Novartis consented to the entry of an order requiring the company to cease and desist from committing violations of the books and records and internal accounting controls provisions of the FCPA.
The Securities and Exchange Commission today announced that Novartis AG, a global pharmaceutical and healthcare company headquartered in Basel, Switzerland, has agreed to pay over $112 million to settle charges that it violated the books and records and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA).
The SEC's order finds that local subsidiaries or affiliates of Novartis or its former subsidiary Alcon Inc. engaged in schemes to make improper payments or to provide benefits to public and private healthcare providers in South Korea, Vietnam, and Greece in exchange for prescribing or using Novartis or Alcon products.
engaged in schemes to make improper payments or to provide benefits to public and private healthcare providers in South Korea, Vietnam, and Greece in exchange for prescribing or using Novartis or Alcon products.
Corporate conductConfirmedAgainst
Novartis took into account HCP prescription sales for sponsorships
Novartis Korea employees considered HCP prescription sales activities when targeting them for sponsorships to incentivize higher prescriptions.
In connection with some congresses, Novartis Korea employees took into account the prescription sales activities of certain HCPs when targeting them for sponsorships in an effort to encourage the HCPs to increase their prescriptions.
Workplace equityConfirmedAgainst
Novartis ends diverse panels due to U.S. policy changes
Novartis told Reuters it will end its use of diverse panels because of evolving U.S. laws and policies.
Novartis told Reuters on Wednesday that evolving laws and policies in the U.S. would require it to change, and listed the end of its use of diverse panels as one immediate change to its own policies.
Novartis told Reuters on Wednesday that evolving laws and policies in the U.S. would require it to change, and listed the end of its use of diverse panels as one immediate change to its own policies.
Workplace equityAllegationAgainst
Novartis is accused of salary discrimination
Novartis faces a lawsuit alleging its former sales rep's salary was $20,000 less than a male colleague pitching the same drug.
Pharmaceutical giant Novartis must face a former sales representative's lawsuit alleging her salary was over $20,000 less than a male colleague pitching the same drug, a Colorado federal judge ruled, saying...
ManufacturingConfirmedYou decide
Novartis opens cancer drug facility in Carlsbad
Novartis opened a new 10,000-square-foot manufacturing facility in Carlsbad to produce cancer drugs as part of a $23 billion U.S. investment plan.
Swiss drugmaker Novartis opened a new 10,000-square-foot manufacturing facility in Carlsbad to make cancer drugs, as part of its promised $23 billion investment push to build out its domestic U.S. facilities over the next five years.
This content was published on Apr 30, 2026 Novartis is expanding its production capacity in the United States, with the announcement of a new site in Morrisville, North Carolina. This plant will bring to seven the number of new sites planned as part of its $23 billion investment plan.
ManufacturingConfirmedYou decide
Novartis opens seventh U.S. plant
Novartis opens seventh plant in the United States, Keystone-SDA.
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization
Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization | FDA
Corporate conductRecallAgainst
Novartis recalls 100 mg Sandimmune and Neoral blister packs
Novartis recalled 100 mg Sandimmune and Neoral blister packages due to failure to meet child-resistant packaging requirements, posing a poisoning risk.
Novartis Recalls 100 mg Sandimmune and Neoral Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning
Novartis Recalls 100 mg Sandimmune and Neoral Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning
Novartis Recalls 100 mg Sandimmune and Neoral Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning
Novartis Recalls 100 mg Sandimmune and Neoral Prescription Drug Blister Packages Due to Failure to Meet Child-Resistant Packaging Requirement; Risk of Poisoning
Johnson & Johnson and Novartis Brussels, 21 October 2011 - The European Commission has opened an antitrust investigation, on its own initiative, to assess whether contractual arrangements between US-based pharmaceutical company Johnson & Johnson and the generic branches of the Swiss-based company Novartis may have had the object or effect of hindering the entry on to the market of generic versions of Fentanyl in The Netherlands.
On 18/10/2011, the European Commission decided to initiate formal antitrust proceedings against the US-based Johnson & Johnson and the Swiss-based Novartis AG, and their respective subsidiaries in the Netherlands, Janssen-Cilag B.V.
Corporate conductConfirmedAgainst
Novartis development eliminates future competition with GSK
Novartis development of BRAF and MEK inhibitors is alleged to eliminate substantial future competition with GSK in inhibitor development and sales.
§ 45, by: Eliminating substantial future competition between GSK and Novartis in a. the development and sale of BRAF-inhibitors; and Eliminating substantial future competition between GSK and Novartis in b. the development and sale of MEK-inhibitors.
§ 45, by: Eliminating substantial future competition between GSK and Novartis in a. the development and sale of BRAF-inhibitors; and Eliminating substantial future competition between GSK and Novartis in b. the development and sale of MEK-inhibitors.
Corporate conductRulingAgainst
The U.S. Nuclear Regulatory Commission (NRC) issued a notice of violation (NOV) to Novartis Manufacturing
On July 31, 2026, the U.S. Nuclear Regulatory Commission (NRC) issued a notice of violation (NOV) to Novartis Manufacturing, LLC, for two Severity Level III violations for the licensee’s failure to: (1) notify the NRC within 24 hours after discovery of an unplanned contamination event that required access to contaminated areas to be restricted for more than 24 hours, as required by Title 10 of the Code of Federal Regulations (10 CFR) 30.50(b)(1); and (2) complete surveys and conduct or facilitate the cleanup of spills in accordance with its “Radioactive Material Contamination and Spill Clean-up” procedure, as required by Condition 19 of NRC License No. 13-35658-01MD.
On July 31, 2026, the U.S. Nuclear Regulatory Commission (NRC) issued a notice of violation (NOV) to Novartis Manufacturing, LLC, for two Severity Level III violations for the licensee’s failure to: (1) notify the NRC within 24 hours after discovery of an unplanned contamination event that required access to contaminated areas to be restricted for more than 24 hours, as required by Title 10 of the Code of Federal Regulations (10 CFR) 30.50(b)(1); and (2) complete surveys and conduct or facilitate the cleanup of spills in accordance with its “Radioactive Material Contamination and Spill Clean-up” procedure, as required by Condition 19 of NRC License No. 13-35658-01MD.
Corporate conductSettlementAgainst
The Federal Trade Commission approved a final order settling charges that Novartis AG's proposed acquisition of Fougera Holdings
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG's proposed acquisition of Fougera Holdings, Inc. was anticompetitive in the markets for the marketing rights to four topical skin care medications.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Novartis AG's proposed acquisition of Fougera Holdings, Inc. was anticompetitive in the markets for the marketing rights to four topical skin care medications.
Another example of this subterfuge came in 2012, when public reports touted a deal for Sandoz Inc. to acquire Fougera Pharmaceuticals, purportedly making Sandoz the largest seller of generic dermatology medicines both globally and in the United States. In reality, however, it was Novartis – not Sandoz – that signed the agreement and paid the $1.5 billion in cash to acquire Fougera.